Site Search

Led by two former Commissioners of the Federal Trade Commission (FTC)–one of whom also served as U.S. Assistant Attorney General for Antitrust at the Department of Justice (DOJ)–Cravath’s highly regarded antitrust practice provides a wealth of experience and insight with respect to formulating global antitrust strategy, securing regulatory clearance for mergers and acquisitions, and bringing or defending against charges of anticompetitive behavior. Clients turn to Cravath for their most significant—and often unprecedented—antitrust concerns, and we have played a central role in industry‑shaping competition matters for decades.

Cravath has an extensive track record of success in federal and state appellate courts across the country, for both appellants and appellees, repeatedly going “the distance in some of the thorniest, most complex trials and appeals” in the last several years. (The American Lawyer) We successfully defend positive results we achieve in the trial courts, including interlocutory appeals and appeals following trial or other disposition, and—in the face of adverse decisions—we persevere to obtain the best outcome for our clients, shaping the law in the process.

Cravath frequently and successfully represents U.S. and non-U.S. entities in domestic and international arbitrations involving diverse industries and various areas of the law. Our representations extend to clients in Asia, Europe, Latin America and the Middle East, as well as sovereign nations, often involving multibillion‑dollar disputes.

On December 8, 2025, Paramount, a Skydance Corporation (“Paramount”), announced it has commenced an all-cash tender offer to acquire all of the outstanding shares of Warner Bros. Discovery, Inc. (“WBD”) for $30.00 per share in cash, equating to an enterprise value of $108.4 billion. Paramount’s proposed transaction is for the entirety of WBD, including the Global Networks segment. Cravath is representing Paramount in connection with the transaction.

On December 6, 2025, Viatris Inc. (“Viatris”), a global healthcare company, announced it has entered into definitive agreements with Biocon Limited (“Biocon”) for the sale of Viatris’s equity stake in Biocon Biologics Limited. Under the definitive agreements, Biocon will acquire all of Viatris’s convertible preferred equity in Biocon Biologics Limited for a total consideration of $815 million, consisting of $400 million in cash and $415 million in newly issued equity shares of Biocon. Cravath is representing Viatris in connection with the transaction.

Cravath partner Nicole M. Argentieri participated in the American Conference Institute’s 42nd Annual Conference on FCPA and Global Anti‑Corruption, which was held from December 3‑4, 2025 in Washington, D.C. Nicole, who co‑chaired the conference, led a fireside chat with the Acting Assistant Attorney General for the Criminal Division Matt Galeotti about the Division’s priorities and revised policies. Nicole also interviewed Emma Luxton, the Director of Operations for the UK Serious Fraud Office about recent updates to SFO’s corporates guidelines and case announcements, and introduced Deputy Attorney General Todd Blanche, who gave his first speech on the state of white collar enforcement.

From the Firm’s inception, challenging pro bono work has been a cornerstone of our practice.

It takes more than great lawyers to make a great law firm. It takes an administrative staff that shares our lawyers’ commitment to quality and excellence. Cravath’s dedicated staff helps sustain our preeminent position among the world’s law firms. Our collaborative environment and singular record of success combine to provide you with an unparalleled opportunity to develop both professionally and personally.